MedinCell Publishes Its Financial Results for the First Semester Of 2022-2023 (April

Regulatory News: MedinCell (Paris:MEDCL): Revenue: €7.7 million (+89% compared to the first half of the previous year) Operating expenses: €19.4 million (+27% compared to the first half of

Related Keywords

United States ,San Antonio ,Texas ,France ,Jaime Arango ,Richard Malamut ,Nicolas Merigeau ,Louis Victor Delouvrier Alban Dufumier ,David Heuz ,Arthristis Innovation Corporation ,Head Of Communications ,Medincell Program ,Drug Administration ,Melinda Gates Foundation ,Company Supervisory Board ,Global Health ,Research Tax Credit ,Teva At Psych Congress ,European Investment Bank ,Regulatory News ,Chief Financial Officer ,Complete Response Letter ,Bill Melinda Gates Foundation ,Psych Congress ,Cell Program ,Research Tax ,Medical Director ,Medical Board ,Executive Board ,Des March ,Medincell ,Ublishes ,Financial ,Results ,First ,Semester ,022 ,023 ,Pril ,September ,